214 related articles for article (PubMed ID: 21572121)
1. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS.
Holland-Fischer P; Grønbæk H; Sandahl TD; Moestrup SK; Riggio O; Ridola L; Aagaard NK; Møller HJ; Vilstrup H
Gut; 2011 Oct; 60(10):1389-93. PubMed ID: 21572121
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
Grønbaek H; Sandahl TD; Mortensen C; Vilstrup H; Møller HJ; Møller S
Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
[TBL] [Abstract][Full Text] [Related]
3. Kupffer cell activation and portal hypertension.
Steib CJ
Gut; 2011 Oct; 60(10):1307-8. PubMed ID: 21708827
[No Abstract] [Full Text] [Related]
4. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
Trebicka J; Krag A; Gansweid S; Appenrodt B; Schiedermaier P; Sauerbruch T; Spengler U
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1218-25. PubMed ID: 21971377
[TBL] [Abstract][Full Text] [Related]
5. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
[TBL] [Abstract][Full Text] [Related]
6. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.
Mortensen C; Karlsen S; Grønbæk H; Nielsen DT; Frevert S; Clemmesen JO; Møller S; Jensen JS; Bendtsen F
Liver Int; 2013 Oct; 33(9):1309-15. PubMed ID: 23763259
[TBL] [Abstract][Full Text] [Related]
7. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests.
Baron A; Gulberg V; Sauter G; Waggershauser T; Reiser M; Gerbes AL
Hepatogastroenterology; 1998; 45(24):2315-21. PubMed ID: 9951915
[TBL] [Abstract][Full Text] [Related]
8. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites.
Alam I; Bass NM; Bacchetti P; Gee L; Rockey DC
Am J Gastroenterol; 2000 Jan; 95(1):199-203. PubMed ID: 10638583
[TBL] [Abstract][Full Text] [Related]
9. Effects of splenic artery occlusion on portal pressure in patients with cirrhosis and portal hypertension.
Luca A; Miraglia R; Caruso S; Milazzo M; Gidelli B; Bosch J
Liver Transpl; 2006 Aug; 12(8):1237-43. PubMed ID: 16741929
[TBL] [Abstract][Full Text] [Related]
10. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
Colombato L
J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
[TBL] [Abstract][Full Text] [Related]
11. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis.
Waidmann O; Brunner F; Herrmann E; Zeuzem S; Piiper A; Kronenberger B
J Hepatol; 2013 May; 58(5):956-61. PubMed ID: 23333526
[TBL] [Abstract][Full Text] [Related]
12. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study.
La Mura V; Abraldes JG; Berzigotti A; Erice E; Flores-Arroyo A; García-Pagán JC; Bosch J
Hepatology; 2010 Jun; 51(6):2108-16. PubMed ID: 20512998
[TBL] [Abstract][Full Text] [Related]
13. Portal levels of the isoprostane F2 alpha-III, a marker of lipid peroxidation, do not correlate with increased portal pressure in cirrhotic patients.
Praticò D; Rossi E; Merli M; Riggio O; FitzGerald GA; Violi F
J Investig Med; 1998 Dec; 46(9):430-4. PubMed ID: 9861778
[TBL] [Abstract][Full Text] [Related]
14. Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites.
Geilswijk M; Thomsen KL; Pedersen EB; Vilstrup H; Grønbæk H
Scand J Gastroenterol; 2015 Apr; 50(4):454-61. PubMed ID: 25637473
[TBL] [Abstract][Full Text] [Related]
15. Hepatic arterial buffer response in patients with advanced cirrhosis.
Gülberg V; Haag K; Rössle M; Gerbes AL
Hepatology; 2002 Mar; 35(3):630-4. PubMed ID: 11870377
[TBL] [Abstract][Full Text] [Related]
16. Cirrhotic patients with a transjugular intrahepatic portosystemic shunt undergoing major extrahepatic surgery.
Kim JJ; Dasika NL; Yu E; Fontana RJ
J Clin Gastroenterol; 2009 Jul; 43(6):574-9. PubMed ID: 19169145
[TBL] [Abstract][Full Text] [Related]
17. [Transjugular intrahepatic portosystemic shunt and combination with percutaneous transhepatic or transsplenic approach for the treatment of portal vein thrombosis with or without cavernomatous transformation].
Han GH; Meng XJ; Yin ZX; Wang JH; He CY; Liang J; Guo XG; Liu J; Ding L; Wu KC; Fan DM
Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1549-52. PubMed ID: 19953883
[TBL] [Abstract][Full Text] [Related]
18. [Effects of percutaneous intrahepatic portosystemic shunt on splanchnic and systemic hemodynamics in patients with portal hypertension].
François E; García-Pagán JC; Bru C; Feu F; Gilabert R; Escorsell A; Bosch J; Rodés J
Gastroenterol Hepatol; 1997 Jan; 20(1):1-4. PubMed ID: 9072189
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of the initial portal pressure gradient reduction after TIPS in patients with cirrhosis.
Biecker E; Roth F; Heller J; Schild HH; Sauerbruch T; Schepke M
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):846-52. PubMed ID: 17873607
[TBL] [Abstract][Full Text] [Related]
20. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis.
Lotterer E; Wengert A; Fleig WE
Hepatology; 1999 Mar; 29(3):632-9. PubMed ID: 10051460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
